Stock Details
TEVA is Teva Pharmaceutical Industries Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 8.35$. Average daily volumn in 3 months 9.97M. Market cap 8.76B



Stock symbol : TEVA. Exchange : NYSE. Currency : USD
Lastest price : 7.89$. Total volume : 10.99M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Teva Pharmaceutical Industries Limited (TEVA)
Last Price
7.89$
Change
0.37
Volume
10.99M

Previous Close7.52
Open7.51
Day Range7.42-7.91
Bid7.74 x 21.5k
Ask7.89 x 27k
Volume10.99M
Average Volume9.97M
Market Cap8.76B
Beta1.18
52 Week Range7.23-10.50
Trailing P/EN/A
Foward P/E3.05
Dividend (Yield %)N/A
Ex-Dividend Date2017-11-27



Financial Details


According to Teva Pharmaceutical Industries Limited's financial reports the company's revenue in 2021 were 15.88B an decrease(-6.25%) over the years 2020 revenue that were of 16.66B. In 2021 the company's total earnings were 417M while total earnings in 2020 were -3.99B(-113.9%).


Loading ...



Organization

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells ac... tive pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Market Cap:
8.76B
Revenue:
15.88B
Total Assets:
47.67B
Total Cash:
2.17B


News about "Teva Pharmaceutical Industries Limited"

ifm-investors-pty-ltd-buys-30190-shares-of-teva-pharmaceutical-industries-limited-nyseteva-image

IFM Investors Pty Ltd Buys 30,190 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Source from : Defense World - 2 days ago

IFM Investors Pty Ltd boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA โ€“ Get Rating) by 22.3% in the first quarter, HoldingsChannel reports. The firm owned 165,346 shares of the ...See details»


sumitomo-mitsui-ds-asset-management-company-ltd-has-512000-stock-position-in-teva-pharmaceutical-industries-limited-nyseteva-image

Sumitomo Mitsui DS Asset Management Company Ltd Has $512,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Source from : Defense World - 1 days ago

Sumitomo Mitsui DS Asset Management Company Ltd trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA โ€“ Get Rating) by 18.8% in the first quarter, Holdings Channel.com reports. The ...See details»


IFM Investors Pty Ltd Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Source from : ETF Daily News - 2 days ago

Shares of NYSE:TEVA opened at $7.89 on Friday. The stockโ€™s 50-day moving average price is $8.31 and its 200-day moving average price is $8.51. Teva Pharmaceutical Industries Limited has a 12 ...See details»


teva-pharmaceutical-appoints-eric-hughes-as-chief-medical-officer-image

Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Source from : Nasdaq - 3 days ago

Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as Senior Vice President of Clinical Development and ...See details»


teva-pharmaceutical-industries-nyseteva-investors-are-sitting-on-a-loss-of-76-if-they-invested-five-years-ago-image

Teva Pharmaceutical Industries (NYSE:TEVA) investors are sitting on a loss of 76% if they invested five years ago

Source from : YAHOO!Finance - 7 days ago

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It ...See details»


Teva Pharmaceutical Industries Limited (TEVA) Quarterly Performance is -5.26%: Here is the Surprise Factor

Source from : investchronicle - 7 days ago

At the end of the latest market close, Teva Pharmaceutical Industries Limited (TEVA) was valued at $7.74. In that particular session, Stock kicked-off at the price of $7.77 while reaching the peak ...See details»


August 12th Options Now Available For Teva Pharmaceutical Industries

Source from : Nasdaq - 4 days ago

Investors in Teva Pharmaceutical Industries Ltd (Symbol: TEVA) saw new options begin trading today, for the August 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...See details»


DNB Asset Management AS Has $1.24 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Source from : ETF Daily News - 8 days ago

Teva Pharmaceutical Industries Limited has a 52-week low of $7.23 and a 52-week high of $10.50. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.73 and a current ratio of 1.07.See details»


Teva Announces Appointment of New Global R&D and Chief Medical Officer

Source from : Stockhouse - 3 days ago

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will ...See details»


New Suit - Class Action

Source from : Law - 7 days ago

Counsel have not yet appeared for the defendants. The case is 2:21-cv-00477, King County et al v. Teva Pharmaceutical Industries Ltd et al.See details»


Generic Drugs Market to Observe Exponential Growth By 2022 to 2030 | Teva Pharmaceuticals Industries Ltd, Mylan N.V, Novartis AG

Source from : Digital Journal - 11 days ago

New Jersey, United States-Generic Drugs Market 2022 โ€“ 2030, Size, Share, and Trends Analysis Research Report Segmented with Type, Component, Application, Region, and Forecast The Generic Drugs ...See details»


Teva Announces Settlement with Aurobindo Resolving AUSTEDOยฎ (deutetrabenazine) Patent Dispute

Source from : The Globe and Mail - 6 days ago

Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo ...See details»


New Suit - Product Liability

Source from : Law - 10 days ago

CVS Health, Teva Pharmaceutical Industries, Walmart and other defendants ... The case is 1:20-cv-08485, Brewster v. Aurobindo Pharma LTD. et al.See details»


interstitial-cystitis-drugs-market-recorded-481-y-o-y-growth-rate-in-2021-evolving-opportunities-with-perrigo-co-plc-pfizer-inc-technavio-image

Interstitial Cystitis Drugs Market Recorded 4.81% Y-O-Y Growth Rate in 2021| Evolving Opportunities with Perrigo Co. Plc & Pfizer Inc | Technavio

Source from : WFMZ-TV - 5 days ago

The Interstitial Cystitis Drugs Market report provides a detailed analysis of the competitive scenario, the pre-and post-COVID-19 impact on businesses, and the market ...See details»